Alembic announces USFDA final approval for Travoprost Ophthalmic Solution USP, 0.004%
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The state-of-the-art facility is expected to be commissioned over the next three years
Subscribe To Our Newsletter & Stay Updated